ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1624

Deletion of HLA-B27 T Cells Underlies the Immunodominant Response to Influenza Infection On Class I MHC Transgenic Mice

Ali Akram1 and Robert D. Inman2, 1Institute of Medical Science and Department of Immunology, University of Toronto and University Health Network (UHN), Toronto, ON, Canada, 2Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: infection and spondylarthropathy, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Infection-related Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: The role of HLA-B27 in modulating host response to infection is undefined, yet has important implications for the mechanism whereby B27 confers susceptibility to arthritis. Despite co-dominant expression of class I MHC (MHC-I) alleles, immune response to viral infections is characterized by a phenomenon called immunodominance (ImDc). The exact mechanisms of ImDc are not clear. Defining factors contributing to ImDc has proved difficult due to multiple MHC-I allele co-expression in humans and normal mice.

Methods: To overcome this limitation, we generated human MHC-I transgenic (Tg) mice which are deficient for endogenous mouse MHC-I molecules (i.e., H2-K-/-/D-/-, DKO) and express only one human MHC-I allele. To assess whether co-expression of additional MHC-I alleles influences the pattern of anti-flu CTL epitope recognition and ImDc, novel double MHC-I Tg mice were established on a DKO background.

Results: In flu-infected, double Tg HLA-A2/B7 or HLA-A2/B27 mice, IFN-γ ELISpot assays with the flu epitopes M1.58-66 (HLA-A2-specific) and NP418-426 (HLA-B7-specific) or NP383-391 (HLA-B27-specific) showed specific recognition of both peptides by both alleles respectively. In contrast, in flu-infected HLA-B7/B27 Tg mice a significantly reduced NP383-restricted CTL response was detected while there was no change in the response level of NP418-restricted CTL. Subsequent flu-specific studies revealed that co-expression of B7 and B27 is associated with i) a partial deletion of Vβ8.1+ B27/NP383-restricted CD8+ T cells and ii) a failure of Vβ12+ CD8+ T cell expansion following flu infection in B7/B27 Tg mice. Using chimeric mice, we confirmed that the lower number of naive B27-restricted CD8+ T cells in B7/B27 Tg mice, compared to single Tg B27 mice, is due to negative selection of B27-restricted Vβ8.1+ CD8+ T cells.

Conclusion: The pattern of allele co-expression critically influences the flu CTL response. The selective deletion of B27-restricted T cells has important implications for models defining the role that HLA-B27 plays in susceptibility to reactive arthritis and ankylosing spondylitis.


Disclosure:

A. Akram,
None;

R. D. Inman,

Abbott, Amgen, Merck, Pfizer, Sanofi-Aventis ,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deletion-of-hla-b27-t-cells-underlies-the-immunodominant-response-to-influenza-infection-on-class-i-mhc-transgenic-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology